JNJ · News · 20260929N
Revenue Performance and Mix
JOHNSON & JOHNSON · 2026-09-29 · Importance 25 · Surprise 32 · No source text
Johnson & Johnson’s second-quarter revenue grew 6.6% year over year. Bank of America expects third-quarter sales of approximately $25.5 billion, in line with consensus estimates. The analyst projects third-quarter revenue growth of 6% year over year, supported by growth in the Pharmaceutical and MedTech segments and launches including Tremfya and Caplyta.
Key facts
- BofA projects J&J third-quarter sales of $25.5 billion and EPS of $2.53. source
- An analyst projected 6% year-on-year revenue growth for Johnson & Johnson. source
- Johnson & Johnson reported Q2 revenue growth of 6.6% year-over-year. source
- Johnson & Johnson's market capitalization was $655.4 billion and its stock was up 33.52% year-to-date. source
- ETFs collectively bought $81.9 million of Johnson & Johnson shares on September 25. source
- A Bank of America analyst said anticipated earnings dilution from IPR&D could cause J&J to report earnings below consensus for Q3. source
- Johnson & Johnson is set to report its Q3 results on October 13. source
- Johnson & Johnson closed at $267.66 in the latest trading session, marking a -1.58% move from the previous day. source
Impact estimates
| metric | direction | stage | expected | basis |
|---|---|---|---|---|
| revenue | positive | contingent | +0.9% | An analyst projected 6% year-on-year revenue growth for Johnson & Johnson. |
| revenue | unclear | contingent | — | BofA projects J&J third-quarter sales of $25.5 billion and EPS of $2.53. |
| net_income | unclear | contingent | — | BofA projects J&J third-quarter sales of $25.5 billion and EPS of $2.53. |